Table 3.
Univariable and multivariable analyses regarding disease-free survival.
| Characteristics (All) | Univariable Analysis | Multivariable Analysis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | Model 1 b | Model 2 c | ||||||||
| HR | 95% CI | p | HR | 95% CI | p | |||||||
| AR, high vs. low a | 0.56 | 0.377 | 0.834 | 0.004 | 0.43 | 0.274 | 0.674 | <0.001 | 0.495 | 0.328 | 0.745 | 0.001 |
| Tumor size (cm), >2 vs. ≤2 | 2.106 | 1.325 | 3.348 | 0.002 | 1.312 | 0.794 | 2.17 | 0.289 | 1.298 | 0.797 | 2.114 | 0.294 |
| Nodal positivity, positive vs. negative | 3.103 | 2.058 | 4.679 | <0.001 | 2.308 | 1.397 | 3.813 | 0.001 | 2.227 | 1.373 | 3.61 | 0.001 |
| Estrogen receptor, positive vs. negative | 0.867 | 0.578 | 1.299 | 0.489 | 1.709 | 0.943 | 3.098 | 0.078 | ||||
| Progesterone receptor, positive vs. negative | 0.872 | 0.589 | 1.29 | 0.492 | 0.696 | 0.418 | 1.159 | 0.164 | ||||
| HER2, positive vs. negative | 1.054 | 0.659 | 1.688 | 0.826 | 0.78 | 0.453 | 1.345 | 0.371 | ||||
| Histologic grade, 3 vs. 1, 2 | 1.411 | 0.961 | 2.073 | 0.079 | 1.316 | 0.857 | 2.022 | 0.21 | ||||
| Lymphovascular invasion, positive vs. negative | 2.306 | 1.561 | 3.406 | <0.001 | 1.692 | 1.065 | 2.69 | 0.026 | 1.545 | 0.991 | 2.409 | 0.055 |
| Age (years), >50 vs. ≤50 | 1.026 | 0.698 | 1.508 | 0.896 | 0.733 | 0.475 | 1.131 | 0.16 | ||||
| Body mass index (kg/m2), >25 vs. ≤25 | 1.056 | 0.715 | 1.559 | 0.784 | 0.916 | 0.603 | 1.389 | 0.679 | ||||
| Operation, mastectomy vs. lumpectomy | 3.676 | 2.013 | 6.714 | <0.001 | 3.162 | 1.627 | 6.146 | 0.001 | 3.037 | 1.643 | 5.613 | <0.001 |
| Radiation therapy, yes vs. no | 0.891 | 0.6 | 1.323 | 0.568 | 1.024 | 0.636 | 1.648 | 0.923 | ||||
| Chemotherapy, yes vs. no | 0.828 | 0.516 | 1.327 | 0.432 | 0.555 | 0.319 | 0.966 | 0.037 | ||||
| Anti-HER2 therapy, yes vs. no | 2.279 | 1.105 | 4.7 | 0.026 | 3.207 | 1.378 | 7.466 | 0.007 | 2.284 | 1.096 | 4.759 | 0.027 |
| Endocrine therapy, yes vs. no | 0.699 | 0.46 | 1.061 | 0.092 | 0.762 | 0.409 | 1.419 | 0.392 | ||||
Abbreviation: AR, androgen receptor; CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hazard ratio. a Expression of AR was classified into high and low using intensity score with the cut-off value of 10% by immunohistochemistry results. b AR factor was adjusted with all of 14 clinicopathologic factors including tumor size, nodal positivity, estrogen receptor, progesterone receptor, HER2, histologic grade, lymphovascular invasion, age, body mass index, operation, radiation therapy, chemotherapy, anti-HER2 therapy, and endocrine therapy. c AR factor was adjusted with 5 clinicopathologic factors, which were statistically significant by univariable analysis, including tumor size, nodal positivity, lymphovascular invasion, operation, and anti-HER2 therapy.